Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... to be associated with poorer survival compared with azacitidine . This analysis further compared the efficacy and the toxicity ... 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... BACKGROUND: In the AZA-001 trial, azacitidine (75 mg/m(2)/d subcutaneously for Days 1-7 of every 28-day ... to first response and the potential benefit of continued azacitidine treatment beyond first response in responders. RESULTS: ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Safety and efficacy of azacitidine in myelodysplastic syndromes.

    ... different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    ... months even in the presence of continuous therapy with azacitidine (AZA). Whether p53 expression status known to confer ...

    Research Article last updated 07/07/2014 - 9:27am.

  5. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.

    ... July 6, 2010 Azacitidine is currently the only drug to have shown a significant ... However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations ... management of Int-2 and high-risk patients receiving azacitidine. Bone Marrow Diseases:  ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) ... the efficacy and safety of combination therapy with azacitidine (75mg/m(2)/d x 5 days) and lenalidomide (10mg/d x 21 days (28-day ...

    Research Article last updated 10/01/2012 - 9:58am.

  7. Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?

    ... patients. In fact, hypomethylating agents (HMA) like azacitidine have been successfully used in clinical trials and achieved ... agent HMA treatment. Currently, combination therapies of azacitidine with lenalidomide appear to be promising thus making them ...

    Research Article last updated 06/20/2013 - 11:05am.

  8. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

    ... two randomized clinical trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, ... aims to provide practical recommendations for the use of azacitidine and the management of its side effects in patients with MDS, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Top expert calls future MDS/AML care “promising”

    ... agents, such as SGI-110 (guadecitabine) or CC-486 (oral azacitidine ). What are the ongoing clinical trials in this space? ...

    Article last updated 11/02/2016 - 11:28am.

  10. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell ...

    Research Article last updated 11/05/2012 - 8:57am.